Results 301 to 310 of about 118,941 (325)

Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential

Clinical Nephrology, 2017
Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou, Kyriakos, Trigkidis, Christos, Kazazis   +2 more
openaire   +2 more sources

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors

Diabetes, obesity and metabolism, 2019
Inhibition of glucose transport in the kidney, to produce glucosuria and thus directly lower blood glucose seems a remarkably simple way to treat diabetes (type 1 or type 2). The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and their
E. Brown, S. Rajeev, D. Cuthbertson, John P H Wilding   +3 more
semanticscholar   +1 more source

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

Expert Opinion on Emerging Drugs, 2013
Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire   +2 more sources

Sodium-Glucose Co-Transport Inhibitors

Drugs, 2010
The kidney plays a major role in glucose homeostasis because of its role in gluconeogenesis and the glomerular filtration and reabsorption of glucose in the proximal convoluted tubules. Approximately 180 g of glucose is filtered daily in the glomeruli of a normal healthy adult. Typically, all of this glucose is reabsorbed with
Joshua J, Neumiller, John R, White, R Keith, Campbell   +2 more
openaire   +2 more sources

Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis

Diabetes, obesity and metabolism, 2018
To assess the possible risk of acute kidney injury (AKI) with the use of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i) as well as changes in estimated glomerular filtration rate (eGFR), hospitalizations and mortality in a real‐world setting.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, G. Chodick, V. Shalev   +4 more
semanticscholar   +1 more source

Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence

Current pharmaceutical design
Atherosclerotic Cardiovascular Disease (ASCVD) is still one of the leading causes of death globally, with Coronary Artery Disease (CAD) being the most prevalent form of ASCVD.
P. Karakasis, D. Patoulias, G. Kassimis, T. Koufakis, A. Klisić, M. Doumas, N. Fragakis, Manfredi Rizzo   +7 more
semanticscholar   +1 more source

Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Diabetes, obesity and metabolism, 2020
To assess the efficacy and safety of combination therapy with a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and a sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) in patients with type 2 diabetes.
C. Mantsiou, T. Karagiannis, Panagiota Kakotrichi, K. Malandris, Ioannis Avgerinos, A. Liakos, A. Tsapas, E. Bekiari   +7 more
semanticscholar   +1 more source

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.

NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2018
Sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) have consistently demonstrated a clinically significant reduction of cardiovascular mortality.
E. Raschi, E. Poluzzi, Francesco Salvo, Francesco Salvo, Antoine Pariente, Antoine Pariente, F. D. Ponti, Giulio Marchesini, Ugo Moretti   +8 more
semanticscholar   +1 more source

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents

Expert Opinion on Therapeutic Patents, 2012
Maintenance of glucose homeostasis in healthy individuals involves SGLT2 (sodium glucose co-transporter 2)-mediated recovery of glucose from the glomerular filtrate which otherwise would be excreted in urine. Clinical studies indicate that SGLT2 inhibitors provide an insulin-independent means to reduce the hyperglycemia that is the hallmark of type 2 ...
openaire   +2 more sources

Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors

Drug and Therapeutics Bulletin, 2023
After initially being licensed as treatment for diabetes, the range of indications for sodium-glucose co-transporter 2 (SGLT2) inhibitors has expanded to include chronic heart failure and chronic kidney disease. This article provides an overview of some of the evidence that supports the use of SGLT2 inhibitors in the management of chronic heart failure
openaire   +2 more sources